{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T05:23:26Z","timestamp":1788326606844,"version":"build-2803163510"},"reference-count":25,"publisher":"The Journal of Rheumatology","issue":"Suppl 3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2025,5,20]]},"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:p>Psoriatic disease (PsD) is a complex, heterogeneous disease with unmet medical needs in terms of its diagnosis, management, and prognosis. The identification of biomarkers could improve the implementation of precision medicine in PsD, but to date, none of these biomarkers have been clinically validated. Biomarkers can support clinical trials in several ways, including (1) diagnostics, (2) drug pharmacodynamics, (3) prognostics for patient selection and monitoring of drug efficacy, and (4) predictive models for clinical outcomes. Biomarkers can sometimes be used for both diagnosis and prognosis. Benefits of biomarkers use may include shorter duration of clinical trials, faster access to new treatments, and a personalized approach to disease management. Several potential biomarkers have recently demonstrated promise for use in PsD, including C1M, a serum biomarker reflecting collagen type I collagen degradation, and C4M, a type IV collagen metabolite, but clinical validation has not yet been completed. Here, and as presented at the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2024 annual meeting, we summarize the status of biomarker discovery for PsD and their overlap with other musculoskeletal diseases such as rheumatoid arthritis and axial spondyloarthritis.<\/jats:p>","DOI":"10.3899\/jrheum.2025-0671","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T12:20:17Z","timestamp":1756729217000},"page":"12-15","source":"Crossref","is-referenced-by-count":0,"title":["Discovery and Clinical Validation of C1M and C4M as Soluble Biomarkers for Diagnosis, Prognosis, and Symptom Prediction in Psoriatic Disease and Other Inflammatory Arthropathies"],"prefix":"10.3899","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0070-1945","authenticated-orcid":false,"given":"Maria-Angeliki","family":"Gkini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7883-6439","authenticated-orcid":false,"given":"Wilson","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3848-5122","authenticated-orcid":false,"given":"Kurt","family":"de Vlam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Chandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4612-1014","authenticated-orcid":false,"given":"Signe Holm","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"key":"2026090121551317000_52.Suppl_3.12.1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2024-0260"},{"key":"2026090121551317000_52.Suppl_3.12.2","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224916"},{"key":"2026090121551317000_52.Suppl_3.12.3","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.3390\/cimb46040186","article-title":"Precision dermatology: a review of molecular biomarkers and personalized therapies","volume":"46","author":"Tan","year":"2024","journal-title":"Curr Issues Mol Biol"},{"key":"2026090121551317000_52.Suppl_3.12.4","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2001.113989"},{"key":"2026090121551317000_52.Suppl_3.12.5","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1093\/oncolo\/oyac130","article-title":"The effect of biomarker use on the speed and duration of clinical trials for cancer drugs","volume":"27","author":"Mohamed","year":"2022","journal-title":"Oncologist"},{"key":"2026090121551317000_52.Suppl_3.12.6","first-page":"634","article-title":"Development of draft validation criteria for a soluble biomarker to be regarded as a valid biomarker reflecting structural damage endpoints in rheumatoid arthritis and spondyloarthritis clinical trials","volume":"34","author":"Maksymowych","year":"2007","journal-title":"J Rheumatol"},{"key":"2026090121551317000_52.Suppl_3.12.7","first-page":"1443","article-title":"Biological biomarkers in psoriatic disease. A review","volume":"35","author":"de Vlam","year":"2008","journal-title":"J Rheumatol"},{"key":"2026090121551317000_52.Suppl_3.12.8","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21677"},{"key":"2026090121551317000_52.Suppl_3.12.9","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/bjd.21627","article-title":"Biomarkers of disease progression in people with psoriasis: a scoping review","volume":"187","author":"Ramessur","year":"2022","journal-title":"Br J Dermatol"},{"key":"2026090121551317000_52.Suppl_3.12.10","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4103\/ijd.ijd_167_24","article-title":"Biomarkers in psoriasis: the future of personalised treatment","volume":"69","author":"Kar","year":"2024","journal-title":"Indian J Dermatol"},{"key":"2026090121551317000_52.Suppl_3.12.11","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/liv.14390","article-title":"Collagen biology and non-invasive biomarkers of liver fibrosis","volume":"40","author":"Karsdal","year":"2020","journal-title":"Liver Int"},{"key":"2026090121551317000_52.Suppl_3.12.12","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-022-00444-x"},{"key":"2026090121551317000_52.Suppl_3.12.13","unstructured":"Karsdal MA , ed. Biochemistry of collagens, laminins and elastin: structure, function and biomarkers. Cambridge: Academic Press; 2016."},{"key":"2026090121551317000_52.Suppl_3.12.14","first-page":"574","article-title":"Differentiating patients with psoriasis from psoriatic arthritis using collagen biomarkers","volume":"41","author":"Holm Nielsen","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"2026090121551317000_52.Suppl_3.12.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557"},{"key":"2026090121551317000_52.Suppl_3.12.16","doi-asserted-by":"crossref","first-page":"723944","DOI":"10.3389\/fmed.2021.723944","article-title":"Early origins of psoriatic arthritis: clinical, genetic and molecular biomarkers of progression from psoriasis to psoriatic arthritis","volume":"8","author":"Pennington","year":"2021","journal-title":"Front Med"},{"key":"2026090121551317000_52.Suppl_3.12.17","first-page":"829","article-title":"Type IV collagen metabolism is associated with disease activity, radiographic progression and response to tocilizumab in rheumatoid arthritis","volume":"36","author":"Gudmann","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"2026090121551317000_52.Suppl_3.12.18","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/art.42921","article-title":"Phase 2 trial of deucravacitinib in psoriatic arthritis: biomarkers associated with disease activity, pharmacodynamics, and clinical responses","volume":"76","author":"FitzGerald","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"2026090121551317000_52.Suppl_3.12.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2015.07.003"},{"key":"2026090121551317000_52.Suppl_3.12.20","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13075-015-0913-x","article-title":"Early changes in blood-based joint tissue destruction biomarkers are predictive of response to tocilizumab in the LITHE study","volume":"18","author":"Bay-Jensen","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2026090121551317000_52.Suppl_3.12.21","doi-asserted-by":"publisher","DOI":"10.1186\/ar4266"},{"key":"2026090121551317000_52.Suppl_3.12.22","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1002\/art.40527","article-title":"Translational biomarkers and ex vivo models of joint tissues as a tool for drug development in rheumatoid arthritis","volume":"70","author":"Kjelgaard-Petersen","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2026090121551317000_52.Suppl_3.12.23","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1093\/rheumatology\/keab758","article-title":"Filgotinib decreases both vertebral body and posterolateral spine inflammation in ankylosing spondylitis: results from the TORTUGA trial","volume":"61","author":"Maksymowych","year":"2022","journal-title":"Rheumatology"},{"key":"2026090121551317000_52.Suppl_3.12.24","unstructured":"Maksymowych W , Tian Y , Xu J , . Filgotinib treatment results in reduction of inflammatory and matrix remodeling biomarkers associated with disease in patients with ankylosing spondylitis [abstract]. Arthritis Rheumatol 2021;73 Suppl 9."},{"key":"2026090121551317000_52.Suppl_3.12.25","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s13075-023-03132-5","article-title":"Extracellular matrix turnover biomarkers reflect pharmacodynamic effects and treatment response of adalimumab in patients with axial spondyloarthritis-results from two randomized controlled trials","volume":"25","author":"Port","year":"2023","journal-title":"Arthritis Res Ther"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2025-0671","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:55:52Z","timestamp":1788324952000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2025-0671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":25,"journal-issue":{"issue":"Suppl 3","published-online":{"date-parts":[[2025,12,1]]},"published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.3899\/jrheum.2025-0671"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2025-0671","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]}}}